Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.

Ritlecitinib is effective and safe for long-term treatment of alopecia areata.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

Baicalin may effectively treat hair loss by inhibiting 5α-reductase.

Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.

Astilbin can potentially calm overactive immune responses, like in Type 1 Diabetes, by suppressing certain cell activities and reducing inflammation.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

Sonidegib and vismodegib have different side effects and reporting patterns.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Deucravacitinib helped a man regrow hair significantly.

Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.

Compound 4 is a promising treatment for hair loss with low toxicity.

Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.

Tofacitinib is effective and safe for treating severe alopecia areata.

Calcipotriol does not improve the effectiveness of squaric acid dibutylester in treating alopecia areata.

An 11-year-old girl with severe hair loss was successfully treated with a new combination therapy.

Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.

Ritlecitinib can help about 14,000 people with severe hair loss.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.

Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.

New compounds with carborane showed anti-androgen effects similar to flutamide.

New isatin-gallate hybrids show promise as antioxidants, cancer treatments, and coronavirus inhibitors.

Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.

Sulphadiazine can cause crystals to form in urine.